 |
|
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
- Externalization strategy
- Geographic strategy
- Molecule type strategy
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
- Establishment of Aventis CropScience Shionogi K.K.
- Establishment of Shionogi-GSK Pharmaceuticals LLC
- Establishment of Boehringer Ingelheim Shionogi Vetmedica Co.
- Establishment of Shionogi Biomedical Laboratories
- Industrial chemicals business transferred to DSL. Japan Co., Ltd.
- Establishment of Shionogi Analysis Center Co.
- M&A strategy
- Current corporate structure
- Ethical pharmaceuticals
- Consumer health
- Diagnostics
- Current management team
- CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate vs. peer set
- Product analysis, 2001-06
- Growth drivers
- Crestor royalties
- Claritine
- Oxycontin
- Imunace
- Growth resistors
- Flumarin
- Vancomycin
- Flomox
- Operating revenue and cost analysis, 2001-06
- Operating revenue/cost analysis
- CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
- Growth drivers
- Finibax
- Crestor royalties
- Duloxetine
- Finibax royalties
- Growth resistors
- Vancomycin
- Flomox
- Flumarin
- Imunace
- Therapy area analysis, 2006-12
- Growth drivers
- Cardiovascular and hematology
- Central nervous system
- Infectious disease
- Respiratory
- Growth resistors
- Oncology
- Gastroenterology
- Musculoskeletal
- Therapy area focus
- Launches and expiries analysis, 2006-12
- Launch portfolio
- Core portfolio
- Expiry portfolio
- Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
- CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular & hematology
- Crestor royalties
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Crestor
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Irbesartan
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Infectious diseases
- Flomox
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Vancomycin
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Flumarin
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Finibax
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Finibax royalties
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Respiratory
- Claritine
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Central nervous system
- Duloxetine
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- Oncology
- Imunace
- Overview
- Sales forecast
- Newsflow
- Competitive landscape
- R&D pipeline
- CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- References
- Abbreviations
- Exchange rates
- List of Tables
- Table 1: Shionogi Corporate Executive Committee
- Table 2: Japanese Pharma peer set overview
- Table 3: Operating revenue/cost analysis ($m), 2001-06
- Table 4: Operating cost ratio analysis (% of total revenues), 2001-06
- Table 5: Product portfolio overview, sales ($m), 2006-12
- Table 6: Therapy area overview, sales ($m), 2006-12
- Table 7: Launch portfolio overview, sales ($m), 2006-12
- Table 8: Core portfolio overview, sales ($m), 2006-12
- Table 9: Expiry portfolio overview, sales ($m), 2006-12
- Table 10: Externally developed portfolio ($m), 2006-12
- Table 11: Molecule type overview, sales ($m), 2006-12
- Table 12: Key products overview
- Table 13: Crestor royalties: overview
- Table 14: Crestor royalties: sales forecast ($m), 2006-12
- Table 15: Crestor royalties: newsflow
- Table 16: Crestor: overview
- Table 17: Crestor: sales forecast ($m), 2006-12
- Table 18: Crestor: newsflow
- Table 19: Irbesartan: overview
- Table 20: Irbesartan: sales forecast ($m), 2006-12
- Table 21: Irbesartan: newsflow
- Table 22: Flomox: overview
- Table 23: Flomox: sales forecast ($m), 2006-12
- Table 24: Flomox: newsflow
- Table 25: Vancomycin: overview
- Table 26: Vancomycin: sales forecast ($m), 2006-12
- Table 27: Vancomycin: newsflow
- Table 28: Flumarin: overview
- Table 29: Flumarin: sales forecast ($m), 2006-12
- Table 30: Flumarin: newsflow
- Table 31: Finibax: overview
- Table 32: Finibax: sales forecast ($m), 2006-12
- Table 33: Finibax: newsflow
- Table 34: Finibax royalties: overview
- Table 35: Finibax royalties: sales forecast ($m), 2006-12
- Table 36: Finibax royalties: newsflow
- Table 37: Claritine: overview
- Table 38: Claritine: sales forecast ($m), 2006-12
- Table 39: Claritine: newsflow
- Table 40: Duloxetine: overview
- Table 41: Duloxetine: sales forecast ($m), 2006-12
- Table 42: Duloxetine: newsflow
- Table 43: Imunace: overview
- Table 44: Imunace: sales forecast ($m), 2005-11
- Table 45: Imunace: newsflow
- Table 46: Shionogi' s R&D pipeline (Phase I-registration)
- Table 47: Shionogi' s indication broadening pipeline (Phase
I-registration)
- Table 48: Exchange rates, 2006
- List of Figures
- Figure 1: Historical and forecast ethical sales performance (% CAGR),
Shionogi and Japanese Pharma peer set
- Figure 2: Therapeutic focus vs. Japanese Pharma peer set (%), 2006
- Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Shionogi
- Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006
- Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012
- Figure 7: SWOT analysis of Shionogi
- Figure 8: Shionogi key developments
- Figure 9: Current corporate structure
- Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06
- Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06
- Figure 12: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06
- Figure 13: Operating revenue/cost analysis ($m), 2001-06
- Figure 14: Operating cost ratio analysis (% of total revenues), 2001-06
- Figure 15: Ethical revenue ($m) and growth rate (%), 2006-12
- Figure 16: Top five products by sales ($m), 2006
- Figure 17: Top five products by sales ($m), 2012
- Figure 18: Growth drivers and resistors by product, 2006-12
- Figure 19: Key strategic products, sales ($m), 2006-12
- Figure 20: Ethical sales by therapy area ($m), 2006-12
- Figure 21: Growth drivers and resistors by therapy area ($m), 2006-12
- Figure 22: Ethical sales by therapy area (%), 2006-12
- Figure 23: Therapy area focus compared with peer set (% total ethical
sales), 2006
- Figure 24: Therapy area focus compared with peer set (% total ethical
sales), 2012
- Figure 25: Launch schedule, sales ($m), 2006-12
- Figure 26: Core products sales growth ($m), 2006-12
- Figure 27: Expiry schedule, sales ($m), 2006-12
- Figure 28: Launch, core and expiry, sales ($m), 2006-12
- Figure 29: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Shionogi
- Figure 30: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 31: Externalization dependency, sales ($m), 2006-12
- Figure 32: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12
- Figure 33: Externalization dependency vs. peer set, % total sales, 2006
- Figure 34: Externalization dependency vs. peer set, % total sales, 2012
- Figure 35: Geographical sales breakdown ($m), 2006-12
- Figure 36: Growth drivers and resistors by geography, sales ($m),
2006-12
- Figure 37: US dependency vs. peer set, % total sales, 2006
- Figure 38: US dependency vs. peer set, % total sales, 2012
- Figure 39: Growth drivers and resistors by molecule type, sales ($m),
2006-12
- Figure 40: Molecule type sales breakdown ($m), 2006-12
- Figure 41: Biologics dependency vs. peer set, % total sales, 2006
- Figure 42: Biologics dependency vs. peer set, % total sales, 2012
- Figure 43: IMS vs. company-reported ethical sales discrepancy ($m),
2006
- Figure 44: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12
|
|
|
|
|
|
View Cart
